"Phospholipovit" vs Placebo in Patients With Combined Hyperlipidemia

Inclusion Criteria: * Availability of signed and dated informed consent of the patient to participate in the study; * Patients with moderate combined hyperlipidemia, defined as: Total cholesterol level 3 - 7 mmol/l, LDL-C 2.5 - 5 mmol/l, TG 1.7 - 4.5 mmol/l, and HDL-C \< 1 mmol/l during screening for men and \< 1.2 mmol/l for women; * Patient consent to use reliable contraceptive methods throughout the study; * The patient's ability to adequately cooperation. Exclusion Criteria: * TG \> 4.5 mmol/l; * Total cholesterol \>7 mmol/l; * LDL cholesterol \>5 mmol/l; * Age less than 30 or older than 75; * Diseases or metabolic disorders that can cause an increase in LDL-C, total cholesterol and TG (secondary dyslipidemia); * Patients receiving high doses of statin drugs (rosuvastatin ≥40 mg, atorvastatin ≥80 mg); * Any acute or exacerbation of chronic infectious diseases; * Type 1 Diabetes mellitus; * Glomerular filtration rate less than 30 ml/min/1.73 m2; * Patients who have undergone acute conditions (infections, injuries, operations) in the period less than 2 months before the start of the study; * Patients with severe dysfunction of the liver and/or kidneys, and/or other vital organs, accompanied by decompensation of their functions; diseases of the central nervous system, with severe impairment of cognitive and mnestic functions; * Persistent increase in liver enzymes activity (transaminases) of unclear etiology or increased liver enzymes activity by 2 or more times from the upper limit of the norm; * Alcohol abuse more than 5 units of alcohol per week (1 unit alcohol is equivalent to 0.325 liters beer, 130 ml wine, 30 ml alcohol); * Drug use; * A history of a positive HIV test result; * Positive test result for hepatitis B and C, syphilis; * A history of hypothyroidism or thyroid-stimulating hormone levels (TSH) exceeding \> 1X upper limit of normal (ULN) during screening; * History of oncological disease during the last 5 years; * Patients diagnosed with porphyria; * Patients diagnosed with myopathy; * Clinically significant abnormal blood test results general urinalysis at screening; * Hypersensitivity to phospholipids or any components of investigational drug; * Indications for drug therapy a list of therapies prohibited during the study; * Any other diseases or conditions that, in the opinion of the investigator, may distort the results of the study and limit the patient's participation in the study; * Pregnancy and lactation; * Patient participation in another clinical trial or use of any investigational drug during 1 month prior to inclusion in the study; * Not using contraception for patients of reproductive age.